Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
•
Psoriatic arthritis
•
General Rheumatology
•
Pulmonology
•
Immunosuppression
Does the presence of calcified granulomas on chest imaging influence your choice of biologic for treatment of psoriatic arthritis (or rheumatoid arthritis)?
Related Questions
How do you approach use of DMARDs and/or biologics for inflammatory arthritis in patients with a history of seizure disorder on anti-epileptic medications?
How do you approach immunosuppression in patients with a positive Interferon Gamma Release Assay and prior intravesicular BCG treatment for bladder cancer?
What is your approach to differentiating RA-ILD from medication toxicity (I.e. from methotrexate)?
Can Dupixent (dupliumab) be safely used in patients who are taking other biologics for rheumatic disease?
Are you comfortable with using NSAIDs in a patient on methotrexate for inflammatory arthritis?
Are there concerns with combining anti-IL5 biologics (mepolizumab or benralizumab) for severe asthma with other biologics for RA (e.g. TNFi)?
Are there any immunosuppressive agents that have been shown to have utility in concurrent idiopathic anaphylaxis?
How do you approach managing nausea and GI side effects when initiating methotrexate?
In a patient with psoriatic arthritis and recurrent pericarditis, would you combine abatacept or other biologics with rilonacept?
How do you approach treating a patient with RA and cirrhosis who did not respond to csDMARDs?
